In vitro activity of sulbactam-durlobactam against colistin-resistant and/or cefiderocol-non-susceptible, carbapenem-resistant Acinetobacter baumannii collected in U.S. hospitals
Recommended Citation
Iovleva A, McElheny CL, Fowler EL, Cober E, Herc ES, Arias CA, Hill C, Baum K, Fowler VG, Jr., Chambers HF, Greenwood-Quaintance KE, Patel R, van Duin D, Bonomo RA, and Doi Y. In vitro activity of sulbactam-durlobactam against colistin-resistant and/or cefiderocol-non-susceptible, carbapenem-resistant Acinetobacter baumannii collected in U.S. hospitals. Antimicrob Agents Chemother 2024; 68(3):0125823.
Document Type
Article
Publication Date
3-6-2024
Publication Title
Antimicrobial agents and chemotherapy
Abstract
The activity of a novel β-lactamase inhibitor combination, sulbactam-durlobactam (SUL-DUR), was tested against 87 colistin-resistant and/or cefiderocol-non-susceptible carbapenem-resistant Acinetobacter baumannii clinical isolates collected from U.S. hospitals between 2017 and 2019. Among them, 89% and 97% were susceptible to SUL-DUR and imipenem plus SUL-DUR, with MIC(50)/MIC(90) values of 2 µg/mL/8 µg/mL and 1 µg/mL/4 µg/mL, respectively. The presence of amino acid substitutions in penicillin-binding protein 3, including previously reported A515V or T526S, was associated with SUL-DUR non-susceptibility.
Medical Subject Headings
Humans; Colistin; Anti-Bacterial Agents; Cefiderocol; Acinetobacter baumannii; Acinetobacter Infections; Sulbactam; Imipenem; Hospitals; Microbial Sensitivity Tests; Drug Combinations; Azabicyclo Compounds
PubMed ID
38289078
ePublication
ePub ahead of print
Volume
68
Issue
3
First Page
0125823
Last Page
0125823
